Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Celsion Corporation
Profile last edited on: 4/27/22      CAGE: 5DUQ2      UEI: T47TFH41YJF8

Business Identifier: Enhancing clinically proven agents in chemotherapy and immunotherapy
Year Founded
1982
First Award
2010
Latest Award
2010
Program Status
Inactive
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

997 Lenox Drive Suite 100
Lawrenceville, NJ 08648
   (609) 896-9100
   esmith@celsion.com
   www.celsion.com
Location: Multiple
Congr. District: 12
County: Mercer

Public Profile

Only minimally SBIR involved and that sometime ago, Celsion Corporation is a biotechnology firm with a f=drug dvelopment focus. The firm's product candidates include ThermoDox -- a heat-activated liposomal encapsulation of doxorubicin currently in a clinical trial for the treatment of primary liver cancer. The firm's pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers.

Extent of SBIR involvement

User Avatar
Phase I Awards
1
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$182,906
Phase II Dollars
$0
Total Awarded
$182,906

Synopsis: Awardee Business Condition

Employee Range
25-49
Revenue Range
2.5M-5M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
NASDAQ : CLSN
IP Holdings
10-14

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2010 1 NIH $182,906
Project Title: New Thermal Sensitive Carboplatin Liposome for Cancer

Key People / Management

  Michael H Tardugno -- President and CEO

  Nicholas Borys -- Vice President and Chief Medical Office

  Jeffrey W Church -- Senior Vice President, Corporate Business Strategy and Investor Relations

  Raj Prabhakar -- Executive Director, Strategic Planning & Business Development

  Robert A Reed -- VP of CMC and Technological OperationsVice President, CMC and Technical Operatio

  Gregory Weaver -- Senior Vice President and Chief Financial Officer

Company News

Jan 07 2016
Celsion Reports Translational Research Data from its Phase 1b Study of GEN-1 Immunotherapy in Recurrent Ovarian Cancer
May 31 2013
Celsion Corporation Announces $9.83 Million Registered Direct Offering
Sep 02 2010
Celsion Receives SBIR Grant To Expand Its Technology Platform